

TRANSLATIONAL ONCOLOGY PROGRAM

We are a founding member of the Transitional Oncology Program (TOPS) which is a Phase I program devoted to new drug development and individualized cancer care. TOPS is headed by one of the world's leaders in drug development, Dr. Daniel Von Hoff. Several of the Phase I studies are listed in our clinical trial updates; however, this is not a complete listing. We are striving to provide treatment options within our community that would normally only be available at tertiary cancer centers.



FIGHT CANCER

FIGHT CANCER

ABOUT TEXAS ONCOLOGY

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve "More breakthroughs. More victories."® in their fights against cancer, right in their own communities. Texas Oncology, a pioneer in community-based cancer care, is an independent oncology practice with sites of service throughout Texas and southeastern New Mexico.

Texas Oncology patients have the opportunity to take part in some of the most promising clinical trials in the nation for a broad range of cancers. Texas Oncology, through its affiliation with the US Oncology Research network, has played a role in the development of 36 cancer-fighting drugs approved by the Food and Drug Administration (FDA).

Texas Oncology is United in Healing with US Oncology, which supports the nation's foremost cancer treatment and research network advancing the quality of cancer care in America. With more than 1,211 physicians at 456 locations in 39 states, the US Oncology network and Texas Oncology provide cancer patients with access to the latest developments in therapies, technology, and clinical research, as well as best-in-class practices to improve the patient experience.

For more information, visit www.UnitedinHealing.com, or visit the company's Web site, www.USOncology.com.

For more information, visit www.TexasOncology.com or call 1-888-864-I CAN (4226).



TEXAS ONCOLOGY-TYLER

Our mission is to provide a caring environment where our patients receive state-of-the-art cancer care and treatment.

PHYSICIANS:

Donald Richards, M.D., Ph.D.

William Hyman, M.D.

Svetislava Vukelja, M.D.

Frank Ward, M.D.

Aparna Kumar, M.D.

Thomas Gregory, M.D.

Mark Saunders, M.D.

CONTACT:

Linda Dunklin, R.N.

903-579-9867

linda.dunklin@usonology.com

OFFICE LOCATION:

Texas Oncology-Tyler

910 E. Houston

Suite 100

Tyler, TX 75762

903-579-9800

Dear Colleagues,

This is a sample of some of the clinical trials currently available at Texas Oncology, Tyler. We currently have more than 50 ongoing clinical studies, which provide our local patients with the very latest agents for the treatment of cancer. We have been involved in the FDA approval of more than 90% of the recently FDA approved anticancer agents. Therefore, our patients have had access to newer more effective agents sometimes years before the general population of cancer patients.

We are making progress in the fight against cancer. However, there is still a strong need to develop newer more effective and less toxic treatments. This will only be accomplished by clinical researches as outlined in this brochure. We encourage you to consider these options for your patients. If you have any questions concerning our clinical research program, please do not hesitate to contact us.

Sincerely,

Donald A. Richards, M.D., Ph.D.

910 E. Houston, Suite 100
Tyler, TX 75762

More breakthroughs. More victories.®



www.TexasOncology.com



More breakthroughs. More victories.®



BREAST

Yondelis Trip Neg MBC or HER2 O/Exp BrCa

Phase II, Multi-Center, Open-Label, clinical trial of Trastuzumab (Yondelis®) in Metastatic Breast Cancer Patients with triple negative profile (ER-, PR-, HER2-), HER2 overexpressing tumors and BRCA1 or BRCA2 mutation carriers.

E7389 vs Ixa in Neuropathy Adv Br Ca

A Phase II, Multi-Center, Randomized, Open-Label study comparing eribulin mesylate and ixabepilone in causing or exacerbating neuropathy in patients with advanced breast cancer.

Neratinib vs Cape/Lap HER2+ Br Ca

A Phase III, Randomized, Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine for the Treatment of ErbB-2-Positive Locally Advanced or Metastatic Breast Cancer.

Gem/Carbo ± BSI201 Triple Neg MetBrCa

A Phase III, Multi-Center, Open-Label, Randomized Trial of Gemcitabine/Carboplatin, with or without BSI-201, in patients with ER, PR, and HER2-negative metastatic breast cancer.

COLON

SPIRITT: FOLFIRI+Panit or BEV 2Ln MCRC

A Multi-Center, Open-Label, Randomized, Phase II Clinical Trial Evaluating Safety and Efficacy of FOLFIRI with Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects with Metastatic Colorectal Cancer with Wild-Type KRAS tumors.

FOLFIRI+/- AMG479/AMG655 2Ln KRAS mutant

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of FOLFIRI in Combination With AMG 479 or AMG 655 Versus FOLFIRI for the Second-Line Treatment of KRAS-Mutant Colorectal Carcinoma.

GASTRIC

Docetaxel+Oxali±Cetux Met Gastric/GEJ

Phase II trial of docetaxel plus oxaliplatin (DOCOX) with or without cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma.

GI STROMAL TUMOR (GIST)

STAR - nilotinib vs imatinib in GIST

A Randomized, Multi-Center Phase III study to evaluate the efficacy and safety of nilotinib versus imatinib in adult patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).

LEUKEMIA

Imat v Nilot FrontLn Ph+ CML-ChronPhase

A Phase III Multi-Center, Open-Label, Randomized study of imatinib versus nilotinib in adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).

Chlorambucil +/- Ofatumumab unTx CLL

A Phase III, Open-Label, Randomized, multicenter trial of Ofatumumab added to Chlorambucil vs. Chlorambucil Monotherapy in previously untreated patients with Chronic Lymphocytic Leukemia.

LYMPHOMAS

Ph III Enz. v Placeb DLBCL Post 1st Ln Tx

PRELUDE: A Phase III Clinical Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin.

Romidepsin in Relapsed PTCL

A Phase II, Multi-Center, Open-Label Trial Evaluating The Activity And Tolerability Of Romidepsin (Depsipeptide, FK228) In Progressive or Relapsed Peripheral T-Cell Lymphoma Following Prior Systemic Therapy.

Rituximab +/- Galiximab in Rel Fol Lymph

A Phase III, Randomized, Double-Blind Study of Galiximab in Combination with Rituximab Compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin's Lymphoma.

Treanda/Rit v R-CVP or RCHOP 1Ln NHL/MCL

An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients with Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL).

PANCREATIC

Gemzar +/- GI-4000 Adj Ras+ Pancreatic

A Phase II Double-Blind, Placebo-Controlled, Multi-Center Adjuvant Trial of the Efficacy, Immunogenicity, and Safety of GI-4000; an Inactivated Recombinant *Saccharomyces cerevisiae* Expressing Mutant Ras Protein Combined with a Gemcitabine Regimen Versus a Gemcitabine Regimen with Placebo, in Patients with Post-resection R0/R1 Pancreatic Cancer with Tumor Sequence Confirmation of Ras Mutations.

LUNG

Tarceva vs Placebo for EGFR+ Adj. NSCLC

A Multi-Center Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Single-agent Tarceva (erlotinib) Following Complete Tumor Resection with or without Adjuvant Chemotherapy in Patients with Stage IB-IIIa Non-small Cell Lung Carcinoma who have EGFR-Positive Tumors.

Ph I IMO2055+Erlotinib+Bevacizumab-NSCLC

Open-Label Phase Ib study of erlotinib plus bevacizumab and IMO-2055 in patients with non-small cell lung cancer who have progressed following initial chemotherapy for advanced or metastatic disease.

Talactoferrin or Plcbo +BSC 3/4 Ln NSCLC

FORTIS-M: A Phase III, Randomized, Double-Blind, Placebo-Controlled study of oral talactoferrin in addition to best supportive care in patients with Non-Small cell lung cancer who have failed two or more prior treatment regimens.

Taxol/Carbo +/-ASA404 1Ln NSCLC

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

T/C +/-anti-IGF1R 1Ln non-adeno NSCLC

Randomized, Open-Label, Phase III trial of CP-751,871 in combination with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer.

Pem/Carbo/Bev vs Tax/Carbo/Bev 1Ln NSCLC

Randomized, Open-Label, Phase III Study of Pemetrexed plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab versus Paclitaxel plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients with Stage IIIB or IV Nonsquamous Non-Small Cell Lung Cancer.

Docetaxel +/- ASA404 in 2Ln NSCLC

A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination with Docetaxel in Second-Line Treatment of Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC).

Carboplatin and Etoposide with or without Obatoclox in Patients with ES-SCLC

A Phase I Followed by a Randomized, Phase II Study of Carboplatin and Etoposide with or without Obatoclox Administered Every 3 Weeks to Patients with Extensive-Stage Small Cell Lung Cancer.

Lucanix in Advanced NSCLC

A Phase III Randomized, Double-Blind, Placebo-Controlled Study of Lucanix Maintenance Therapy for Stage III/IV NSCLC Subjects Who Have Responded to or Have Stable Disease Following One Regimen of Front-Line, Platinum-Based Combination Chemotherapy.

RENAL

Axitinib vs Sorafenib Second Line RCC

Axitinib (AG-013736) as Second Line Therapy for Metastatic Renal Cell Cancer: AXIS Trial.

Pazopanib vs Sunitinib 1st Ln Adv/mRCC

Study VEG108844, a Study of Pazopanib versus Sunitinib in the Treatment of Subjects with Locally Advanced and/or Metastatic Renal Cell Carcinoma.

SOLID TUMORS

Ph I PG-11047 in Different Combinations

A Phase I Open-Label, Multi-Center, Dose-Escalation Study to Determine the Maximum Tolerated Dose (MTD), Dose Limiting Toxicity (DLT), Safety and Pharmacokinetics of PG-11047 when Used in Individual Combinations with 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Fluorouracil or 7) Sunitinib in Patients with Advanced Solid Tumors or Lymphoma (47-01-002).

Phase IB of LY573636 w/different combos

A Phase Ib, Multi-Center, Dose-Escalation Study of LY573636-sodium in Combination with 1) Gemcitabine HCl or 2) Docetaxel or 3) Temozolomide or 4) Cisplatin in Patients with Advanced Solid Tumors.

LY2603618 + Gem in solid & pancr

A Randomized Phase Ib/II study of LY2603618 IV administered 1 day after gemcitabine IV every 28 days versus gemcitabine for patients with pancreatic cancer.

LY2382770 (TGFb mAb) metastatic/solid

A Phase I Dose-Escalation Study of LY2382770, a TGF-beta Monoclonal Antibody, in Patients with Metastatic Cancer.

UROTHELIAL

Gemzar, Cisp, Sunitinib 1st Ln Uroth Ca

Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma.